<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936546</url>
  </required_header>
  <id_info>
    <org_study_id>2009/183</org_study_id>
    <nct_id>NCT00936546</nct_id>
  </id_info>
  <brief_title>A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy</brief_title>
  <official_title>A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of the combination of rituximab and&#xD;
      methotrexate to treat disabling fibrosing skin disorders.Rituximab will be administered at&#xD;
      baseline and month 6. The drug will be considered efficacious if the skin thickness&#xD;
      diminishes substantially.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 3, 2015</completion_date>
  <primary_completion_date type="Actual">June 3, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testing the safety of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.</measure>
    <time_frame>Safety will be evaluated at baseline, month 3, 6, 12, 15, 18, 24, 36, 48 and 60.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing the efficacy of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.</measure>
    <time_frame>Efficacy will be evaluated at baseline, month 3, 6, 12, 15, 18, 24, 36, 48 and 60.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Mabthera, Rituximab 1000 mg I.V.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (Fe) male &gt;, = 18 years&#xD;
&#xD;
          -  Fibrosing skin disorder, not fulfilling the ACR criteria for diffuse SSc&#xD;
&#xD;
          -  Inadequate response to methotrexate (at least 12 weeks 10 mg/w, except if not&#xD;
             tolerated or contra-indicated&#xD;
&#xD;
          -  Debilitating disease defined by either one of the following:&#xD;
&#xD;
          -  Restriction of mobility&#xD;
&#xD;
          -  Disfiguration: eg: facial involvement&#xD;
&#xD;
          -  Severe Internal Organ involvement&#xD;
&#xD;
          -  Contraception for women with childbearing potential. Sexual abstinence is an&#xD;
             alternative to contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FVC&lt;, = 50%&#xD;
&#xD;
          -  LVEF&lt;, = 40% of predicted value,&#xD;
&#xD;
          -  DLCO&lt;, = 40% of predicted value&#xD;
&#xD;
          -  Exclusion criteria as specifically described in the protocol for anti-CD-20:&#xD;
&#xD;
          -  Lack of peripheral venous access.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease).&#xD;
&#xD;
          -  Evidence of significant uncontrolled concomitant disease such as, but not limited to,&#xD;
             nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the&#xD;
             investigator's opinion, would preclude patient participation.&#xD;
&#xD;
          -  Primary or secondary immunodeficiency (history of, or currently active), including&#xD;
             known history of HIV infection.&#xD;
&#xD;
          -  Known active infection of any kind (excluding fungal infections of mail beds), or any&#xD;
             major episode of infection requiring hospitalization or treatment with i.v.&#xD;
             anti-infectives within 4 weeks of baseline or completion of oral anti-infectives&#xD;
             within 2 weeks prior to baseline.&#xD;
&#xD;
          -  History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within&#xD;
             52 weeks prior to baseline.&#xD;
&#xD;
          -  History of serious recurrent or chronic infection (for screening for a chest infection&#xD;
             a chest radiograph will be performed at screening if not performed within 12 weeks&#xD;
             prior to screening).&#xD;
&#xD;
          -  History of cancer, including solid tumors, hematologic malignancies and carcinoma in&#xD;
             situ (except basal cell and squamous cell carcinoma of the skin that have been excised&#xD;
             and cured).&#xD;
&#xD;
          -  History of a severe allergic or anaphylactic reaction to a biologic agent or known&#xD;
             hypersensitivity to any component of rituximab or to murine proteins.&#xD;
&#xD;
          -  Concurrent treatment with any biologic agent or DMARD other than MTX. Treatment must&#xD;
             be discontinued 14 days prior to baseline , except for the following: azathioprine for&#xD;
             ≥ 28 days; leflunomide for ≥ 8 weeks (or ≥ 14 days after 11 days of standard&#xD;
             cholestyramine or activated charcoal washout); infliximab ≥ 8 weeks; adalimumab ≥&#xD;
             weeks.&#xD;
&#xD;
          -  Previous treatment with &gt; 1 biological agent.&#xD;
&#xD;
          -  Treatment with any investigational agent within 28 days of baseline or 5 half-lives of&#xD;
             the investigational drug (which ever is the longer).&#xD;
&#xD;
          -  Receipt of any vaccine within 28 days prior to baseline&#xD;
&#xD;
          -  Intolerance or contraindications to i.v. glucocorticoids.&#xD;
&#xD;
          -  Positive serum human chorionic gonadotropin (hCG) measured at screening or a positive&#xD;
             pregnancy test prior to the first rituximab infusion.&#xD;
&#xD;
          -  Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody&#xD;
             (HBcAb) or hepatitis C serology.&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL.&#xD;
&#xD;
          -  Concentrations of serum IgG and/or IgM below 5.0 and 0.40 mg/mL, respectively.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 X 10³/µL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip De Keyser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>website of the University Hospital Ghent</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

